IMM02-KORA not checked

Immunis, Inc. · TRK-820 · MT-9938

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total

What this is

How it works
How it works isn't classified yet
How it’s given
“IMM02-KORA (nalfurafine hydrochloride) is a synthetic selective kappa opioid receptor agonist (KORA).”In the company’s words, NCT07905976 on ClinicalTrials.gov
Tested for
Dyskinesia, Medication-induced, Dyskinesia, Drug-Induced
Main trialPhase 1
“The goal of this clinical trial is to test Safety and tolerability of single and repeated dose of IMM02-KORA in subjects with PD-associated dyskinesia.”In the company’s words, NCT07905976 on ClinicalTrials.gov
Other names
TRK-820 · MT-9938 · AC-820 · KORA

Other drugs for Dyskinesia, Medication-induced

All 4 drugs for Dyskinesia, Medication-induced

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Not yet recruiting 30 Dec 2027 Safety and Tolerability of Single and Repeated Dose of IMM02-KORA in PD-associated Dyskinesia
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow IMM02-KORA

Following is part of Solo: you see every change to IMM02-KORA the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in